英国制药商葛兰素史克周一表示，已向美国食品和药物管理局提交申请，将其呼吸道合胞病毒（RSV）疫苗Arexvy的使用范围扩大到50岁以下、患病风险较高的成年人。

Group 1 - The core point of the article is that GlaxoSmithKline has submitted an application to the U.S. Food and Drug Administration to expand the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under 50 who are at high risk of illness [1] Group 2 - The application aims to broaden the vaccine's target demographic, potentially increasing its market reach and addressing a significant health concern among vulnerable populations [1]